Following annual results that demonstrated the firm’s resilience in the face of unprecedented challenges from the coronavirus pandemic in 2020, Sandoz will pursue future growth by focusing on a “pure” generics and biosimilars model that is unique among its peer group of the off-patent industry’s biggest companies, CEO Richard Saynor has told Generics Bulletin in an exclusive interview.
Reporting its annual results for 2020, Sandoz recently revealed that a turnover boost from its Biopharmaceuticals unit had offset a...
